Gastric Cancer with Peritoneal Metastases: Current Status and Prospects for Treatment

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Mar 29

PMID 36980663

Authors

Israel Manzanedo

Fernando Pereira

Estibalitz Perez-Viejo

Angel Serrano

Affiliations

Soon will be listed here.

Abstract

Gastric cancer (GC) has a poor prognostic and only one in four patients will have survived by 5 years after diagnosis. These poor results are due to the fact that most patients are diagnosed in advanced stages; peritoneal metastases (PM) are especially frequent and are difficult to treat. Currently, PM are considered a terminal stage of GC with a poor survival rate and are treated with palliative systemic chemotherapy. Since the beginning of the century, the treatment of PM from different origins has evolved; cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have become the treatment of choice for many malignant diseases that affect the peritoneum. CRS and HIPEC have also been used for patients with GC and PM, achieving survival results that have never been achieved when using systemic chemotherapy alone. The use of HIPEC can even prevent the development of peritoneal recurrences in patients with locally advanced GC as adjuvant therapy, can reduce the volume of peritoneal disease as neoadjuvant therapy, and can control symptoms in a palliative setting. The aim of this review is to collate the current scientific evidence regarding the treatment of PM of GC origin with surgery and intraperitoneal chemotherapy.

Citing Articles

Efficacy and Insights from an Extensive Series of Cytoreductive Surgery for Peritoneal Neoplasms: A High-Volume Single-Center Experience.

Aulicino M, Santullo F, DAnnibale G, Abatini C, Attalla El Halabieh M, Orsini C Cancers (Basel). 2025; 16(24.

PMID: 39766128 PMC: 11726991. DOI: 10.3390/cancers16244229.

Extracellular vesicle-packaged miR-4253 secreted by cancer-associated fibroblasts facilitates cell proliferation in gastric cancer by inducing macrophage M2 polarization.

Duan X, Yu X, Gan J Cancer Biol Ther. 2024; 25(1):2424490.

PMID: 39505708 PMC: 11542604. DOI: 10.1080/15384047.2024.2424490.

Photoimmunotherapy using indocyanine green-loaded Codium fragile polysaccharide and chitosan nanoparticles suppresses tumor growth and metastasis.

Ryu D, Park H, An E, Kim S, Kim D, Lim D J Nanobiotechnology. 2024; 22(1):650.

PMID: 39438917 PMC: 11515802. DOI: 10.1186/s12951-024-02944-0.

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Gastric Cancer Peritoneal Metastases: Results from the Lithuanian PIPAC Program.

Luksta M, Bausys A, Gendvilaite N, Bickaite K, Rackauskas R, Paskonis M Cancers (Basel). 2024; 16(17).

PMID: 39272850 PMC: 11394265. DOI: 10.3390/cancers16172992.

Non-Coding RNAs in Peritoneal Carcinomatosis: From Bench to Bedside.

Bohosova J, Ashraf N, Slaby O, Calin G Cancers (Basel). 2024; 16(17).

PMID: 39272819 PMC: 11394633. DOI: 10.3390/cancers16172961.

References

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

Zhu Z, Tang R, Yan M, Chen J, Yang Q, Li C . Efficacy and safety of intraoperative peritoneal hyperthermic chemotherapy for advanced gastric cancer patients with serosal invasion. A long-term follow-up study. Dig Surg. 2006; 23(1-2):93-102. DOI: 10.1159/000093778. View

Rau B, Brandl A, Piso P, Pelz J, Busch P, Demtroder C . Peritoneal metastasis in gastric cancer: results from the German database. Gastric Cancer. 2019; 23(1):11-22. DOI: 10.1007/s10120-019-00978-0. View

Noiret B, Piessen G, Eveno C . Update of randomized controlled trials evaluating cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in prevention and therapy of peritoneal metastasis: a systematic review. Pleura Peritoneum. 2022; 7(2):51-61. PMC: 9166620. DOI: 10.1515/pp-2021-0152. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Gonzalez-Moreno S, Kusamura S, Baratti D, Deraco M . Postoperative residual disease evaluation in the locoregional treatment of peritoneal surface malignancy. J Surg Oncol. 2008; 98(4):237-41. DOI: 10.1002/jso.21072. View

Cui H, Ge H, Bai X, Zhang W, Zhang Y, Wang J . Effect of neoadjuvant chemotherapy combined with hyperthermic intraperitoneal perfusion chemotherapy on advanced gastric cancer. Exp Ther Med. 2014; 7(5):1083-1088. PMC: 3991504. DOI: 10.3892/etm.2014.1599. View

Quenet F, Elias D, Roca L, Goere D, Ghouti L, Pocard M . Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021; 22(2):256-266. DOI: 10.1016/S1470-2045(20)30599-4. View

Facchiano E, Risio D, Kianmanesh R, Msika S . Laparoscopic hyperthermic intraperitoneal chemotherapy: indications, aims, and results: a systematic review of the literature. Ann Surg Oncol. 2012; 19(9):2946-50. DOI: 10.1245/s10434-012-2360-0. View

10.

Pereira F, Serrano A, Manzanedo I, Perez-Viejo E, Gonzalez-Moreno S, Gonzalez-Bayon L . GECOP-MMC: phase IV randomized clinical trial to evaluate the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) with mytomicin-C after complete surgical cytoreduction in patients with colon cancer peritoneal metastases. BMC Cancer. 2022; 22(1):536. PMC: 9097342. DOI: 10.1186/s12885-022-09572-7. View

11.

Kusamura S, Bhatt A, Hubner M, Villeneuve L, Deraco M, Bakrin N . The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: Methodology. Ann Surg Oncol. 2023; 30(4):2508-2519. DOI: 10.1245/s10434-022-12990-3. View

12.

Brucher B, Piso P, Verwaal V, Esquivel J, Derraco M, Yonemura Y . Peritoneal carcinomatosis: cytoreductive surgery and HIPEC--overview and basics. Cancer Invest. 2012; 30(3):209-24. DOI: 10.3109/07357907.2012.654871. View

13.

van Driel W, Koole S, Sikorska K, Schagen van Leeuwen J, Schreuder H, Hermans R . Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N Engl J Med. 2018; 378(3):230-240. DOI: 10.1056/NEJMoa1708618. View

14.

Chia C, You B, Decullier E, Vaudoyer D, Lorimier G, Abboud K . Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility?. Ann Surg Oncol. 2016; 23(6):1971-9. DOI: 10.1245/s10434-015-5081-3. View

15.

Martins M, Santos-Sousa H, Araujo F, Nogueiro J, Sousa-Pinto B . Impact of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer with Peritoneal Carcinomatosis: A Systematic Review and Meta-analysis. Ann Surg Oncol. 2022; 29(12):7528-7537. DOI: 10.1245/s10434-022-12312-7. View

16.

Gamboa A, Winer J . Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer. Cancers (Basel). 2019; 11(11). PMC: 6896138. DOI: 10.3390/cancers11111662. View

17.

Manzanedo I, Pereira F, Serrano A, Perez-Viejo E . Review of management and treatment of peritoneal metastases from gastric cancer origin. J Gastrointest Oncol. 2021; 12(Suppl 1):S20-S29. PMC: 8100722. DOI: 10.21037/jgo-20-232. View

18.

Alyami M, Bonnot P, Mercier F, Laplace N, Villeneuve L, Passot G . Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer. Eur J Surg Oncol. 2020; 47(1):123-127. DOI: 10.1016/j.ejso.2020.05.021. View

19.

Kuramoto M, Shimada S, Ikeshima S, Matsuo A, Yagi Y, Matsuda M . Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma. Ann Surg. 2009; 250(2):242-6. DOI: 10.1097/SLA.0b013e3181b0c80e. View

20.

Rihuete Caro C, Manzanedo I, Pereira F, Carrion-Alvarez L, Serrano A, Perez-Viejo E . Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with gastric cancer and peritoneal carcinomatosis. Eur J Surg Oncol. 2018; 44(11):1805-1810. DOI: 10.1016/j.ejso.2018.06.036. View